Drug Trial Radar · NCT03320330
Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Jan 31, 2018
Primary completion
Dec 31, 2020
Study completion Jun 30, 2024
Sponsor
- Lead sponsor
- Children's Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Oct 25, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/II trial studies the side effects and best dose of pepinemab and to see how well it works in treating younger patients with solid tumors that have come back after treatment, or do not respond to treatment. Immunotherapy with monoclonal antibodies, such as pepinemab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Conditions
- Recurrent Malignant Solid Neoplasm
- Recurrent Osteosarcoma
- Refractory Malignant Solid Neoplasm
- Refractory Osteosarcoma
Interventions
Laboratory Biomarker AnalysisOther
Correlative studies
PepinemabBiological
Given IV
Pharmacological StudyOther
Correlative studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose Limiting ToxicitiesTime frame: Up to 28 days
- Patients Who Had Grade 3 or Above Toxicities With the Three Attributions, 'DEFINITE', 'POSSIBLE','PROBABLE'Time frame: Up to 28 days
- Half-lifeTime frame: Prior to, at the end of, and 2 hours after infusion on day 1 of cycles 1-2; days 4 & 8 of cycle 1; prior to and the end of infusion on day 15 of cycle 1; prior to start of infusion on day 15 of cycle 2; prior to start of infusion on day 1 of cycles 3+
- Time to Maximum Concentration (T Max)Time frame: Prior to, at the end of, and 2 hours after infusion on day 1 of cycles 1-2; days 4 & 8 of cycle 1; prior to and the end of infusion on day 15 of cycle 1; prior to start of infusion on day 15 of cycle 2; prior to start of infusion on day 1 of cycles 3+
- Maximum Concentration (C Max)Time frame: Prior to, at the end of, and 2 hours after infusion on day 1 of cycles 1-2; days 4 & 8 of cycle 1; prior to and the end of infusion on day 15 of cycle 1; prior to start of infusion on day 15 of cycle 2; prior to start of infusion on day 1 of cycles 3+
- Area Under Curve (AUC)Time frame: Prior to, at the end of, and 2 hours after infusion on day 1 of cycles 1-2; days 4 & 8 of cycle 1; prior to and the end of infusion on day 15 of cycle 1; prior to start of infusion on day 15 of cycle 2; prior to start of infusion on day 1 of cycles 3+
- ClearanceTime frame: Prior to, at the end of, and 2 hours after infusion on day 1 of cycles 1-2; days 4 & 8 of cycle 1; prior to and the end of infusion on day 15 of cycle 1; prior to start of infusion on day 15 of cycle 2; prior to start of infusion on day 1 of cycles 3+
- Disease Control Rate (Part A)Time frame: Up to 4 months
- Response (Complete Response or Partial Response) (Part B)Time frame: Up to 168 days
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital of Alabama
Birmingham, Alabama
Children's Hospital Los Angeles
Los Angeles, California
Children's Hospital of Orange County
Orange, California
UCSF Medical Center-Mission Bay
San Francisco, California
Children's Hospital Colorado
Aurora, Colorado
Yale University
New Haven, Connecticut
Children's National Medical Center
Washington D.C., District of Columbia
Children's Healthcare of Atlanta - Egleston
Atlanta, Georgia
Lurie Children's Hospital-Chicago
Chicago, Illinois
Riley Hospital for Children
Indianapolis, Indiana
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland
Dana-Farber Cancer Institute
Boston, Massachusetts
C S Mott Children's Hospital
Ann Arbor, Michigan
University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota
Washington University School of Medicine
St Louis, Missouri
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania
Saint Jude Children's Research Hospital
Memphis, Tennessee
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, Texas
University of Texas Health Science Center at San Antonio
San Antonio, Texas
Children's Hospital of The King's Daughters
Norfolk, Virginia
Seattle Children's Hospital
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.